Pilot neoadjuvant trial in breast cancer with combination of ABI-007 (Abraxane) [paclitaxel] and GW572016 (lapatinib).

Trial Profile

Pilot neoadjuvant trial in breast cancer with combination of ABI-007 (Abraxane) [paclitaxel] and GW572016 (lapatinib).

Active, no longer recruiting
Phase of Trial: Phase 0

Latest Information Update: 08 Feb 2018

At a glance

  • Drugs Lapatinib (Primary) ; Paclitaxel (Primary)
  • Indications Breast cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 02 Feb 2018 Planned End Date changed from 1 Aug 2015 to 1 Aug 2020.
    • 10 Jun 2017 Biomarkers information updated
    • 24 Sep 2014 Planned End Date changed from 1 Aug 2014 to 1 Aug 2015 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top